France-based OSE Immunotherapeutics’ (OSE) Phase II CoTikiS study of lusvertikimab has met primary and secondary endpoints, showing high rates of clinical and endoscopic remission after ten ...

A third of women infrequently, if ever, orgasm during sex. It’s a major inequity, one that Osé founder Lora Haddock was trying to solve when she came up against another: sexism in tech.